Abnormal levels of AD imaging markers can be quantified with specific positron emission tomography (PET) tracers, such as 11C-Pittsburgh Compound-B (PiB) [35], 18F-florbetapir [36], 18F-flutemetamol [37], and 18F-florbetaben [38] for Aβ, and 18F-flortaucipir (AV-1451) [39], 18FMK-6240 [40], 18F-PI-2620 [41], and 18F-RO-948 PET [42] for tau. Here, MAPT is linked to Alzheimer disease.